Search the Newsreel

Nephros says its service offerings nearly tripled during Q2

Nephros (Nasdaq: NEPH) reported record second-quarter 2026 net revenue of $6.0 million, a 36% increase year-over-year, with core programmatic revenue growing 27%. The company's service offerings nearly tripled compared to the prior year, reflecting increased customer demand for installation, replacement, and water management support. …

Smith & Nephew (LON:SN) Price Target Lowered to GBX 1,290 at JPMorgan Chase & Co.

JPMorgan cuts Smith & Nephew stock rating on market slowdown

JPMorgan downgraded Smith & Nephew PLC to Neutral from Overweight, citing a slowdown in the orthopaedics market and the company's loss of market share in knees and hips. The firm also lowered its price target to GBP12.90 from GBP14.38 and expressed skepticism about the …

JPMorgan cuts Smith & Nephew stock rating on market slowdown By Investing.com

Nephros Q2 2026 Earnings: Revenue Rises 36% as Tariff Refund Lifts Margins

Nephros reported a 36% increase in Q2 2026 net revenue to $6.017 million, with diluted EPS rising to $0.11, significantly boosted by a one-time $0.6 million tariff refund. While the refund inflated profitability, core programmatic revenue still grew 27%, and service-related revenue nearly tripled. …

Smith+Nephew celebrates mobility, recovery and football's greatest traditions during Pro Football Hall of Fame Enshrinement Week

Smith+Nephew, the official Joint Replacement and Sports Medicine Technology Partner of the Pro Football Hall of Fame, is celebrating mobility, recovery, and football traditions during the 2026 Pro Football Hall of Fame Enshrinement Week in Canton, Ohio. The company will host an interactive booth …

Nephros to File Q2 Results After Close, Host 4:30 ET Call

Nephros (Nasdaq: NEPH) announced it will file its second-quarter 2026 financial results after market close on Thursday, August 06, 2026. The company will host a conference call on the same day at 4:30 p.m. ET. Dial-in details for domestic and international participants, along with …

Smith+Nephew Cuts 2026 Outlook Amid Orthopedics Decline

Smith+Nephew has lowered its full-year 2026 revenue guidance from 6% to 4% due to a disappointing Q2, with revenue growing only 1.6% and orthopedics experiencing a decline. Despite this, the company is maintaining its profit guidance by implementing additional efficiency savings from its 12-Point …

Nephros Schedules Second Quarter 2026 Financial Results Conference Call

Nephros, Inc. announced it will file its second quarter financial results on Thursday, August 06, 2026, after market close and will host a conference call on the same day at 4:30 pm ET. The company is a leading water technology provider, offering filtration solutions …

Smith & Nephew Delivers Strong H1 2026 Profit but Cuts Full-Year Revenue Outlook

Higher profit but softer sales at Smith+Nephew (NYSE: SNN)

Smith+Nephew reported higher H1 2026 profits, with trading profit increasing to $566 million and adjusted EPS rising 11.0% to 47.7¢, driven by efficiency savings. However, the company trimmed its full-year revenue growth outlook from around 6% to 4% due to softer sales in Orthopaedics …

REG - Smith & Nephew Plc - Half-Year Report

Smith+Nephew announced its Q2 and H1 2026 results, reporting strong H1 profit growth despite softer revenue growth. The company reaffirmed its full-year guidance for trading profit, free cash flow, and adjusted ROIC, even as it reduced its full-year revenue growth outlook from approximately 6% …

Smith & Nephew plc Provides Earnings Guidance for the Second Half of 2026

Smith & Nephew plc has issued earnings guidance for the second half of 2026, projecting a revenue growth rate between 5.0% and 5.5%. This forecast represents an increase in growth compared to the first half of the year. The announcement was made on August …

Smith & Nephew cuts revenue growth but cost controls pay off

Smith & Nephew SNATS (NYSE:SNN) Announces Quarterly Earnings Results, Misses Estimates By $0.46 EPS

Earnings call transcript: Smith & Nephew Q2 2026 revenue miss weighs on shares

Smith & Nephew (SNN) reported Q2 2026 earnings with underlying revenue growth of 1.6%, below expectations due to softness in U.S. Orthopaedics and Advanced Wound Bioactives. Despite a revised full-year revenue outlook to around 4%, the company maintained its profit and cash flow guidance, …

Smith+Nephew (NYSE: SNN) trims 2026 growth to 4% but keeps profit goals

Smith+Nephew has revised its full-year 2026 underlying revenue growth forecast down to around 4% from an earlier estimate of 6%, attributed to softer-than-expected first-half growth and pressures in US Orthopaedics and Advanced Wound Bioactives. Despite this reduction in revenue outlook, the company maintains its …

Smith & Nephew plc Reports Earnings Results for the Half Year Ended June 27, 2026

Why Is Smith & Nephew (LSE:SN) Facing Fresh Market Attention?

Smith & Nephew Lowers Sales Growth Forecast Following Softer Second Quarter

Smith & Nephew has reduced its full-year revenue growth forecast after a weaker-than-expected second quarter, impacted by lower U.S. knee implant sales and changes in wound care reimbursement rules. Despite this, the company maintained its profit growth and free cash flow guidance due to …

Smith & Nephew cuts sales outlook after weak US trading

Smith & Nephew has lowered its full-year revenue growth forecast to approximately 4% due to weaker-than-anticipated performance in its US orthopaedics and wound care businesses during the second quarter. Despite this, the company maintained its guidance for trading profit, free cash flow, and return …

UK's Smith+Nephew cuts 2026 revenue view on weak US knee implant demand

UK Stock Market News: SEGRO, Smith & Nephew, AG Barr

Smith & Nephew SNATS (NYSE:SNN) Trading Down 5.8% on Disappointing Earnings

Smith & Nephew plc 2026 Q2 - Results - Earnings Call Presentation (NYSE:SNN) 2026-08-04

Smith & Nephew H1 Profit Rises

(RTTNews) - Smith & Nephew Plc (SNN, SN.L) reported that its first half profit before tax totaled $380 million compared to $362 million, a year ago. For the half year ended June 27, 2026, attributable profit was $303 million compared to $293 million in …

Smith & Nephew (NYSE: SNN) details 839.9M voting shares and treasury stock

Smith & Nephew plc has updated its voting share capital as of July 31, 2026, comprising 839,857,161 ordinary shares with voting rights. This figure excludes 37,876,589 treasury shares from its total issued share capital of 877,733,750 shares. Shareholders are instructed to use the voting …

Nephros Inc (NEPH) Financial Health: Profitability & Balance Sheet Analysis

The article provides an analysis of Nephros Inc's (NEPH) financial health, noting its current financial score of 6.42, ranking 125 out of 159 in its industry. The company's financial status is described as robust, with low operating efficiency, and it recently reported a 6.87% …

Nano Dimension and 4 More Stocks See Action From Activist Investors

Activists also report to the SEC on Smith & Nephew, Navigator Holdings, Global Net Lease, and Radcom. Continue Reading

Nephros Inc (NEPH) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis for Nephros Inc (NEPH), detailing its current valuation score, P/E ratio, and market data. It highlights that the company's valuation score is 8.25, placing it 75th in its industry, and notes its P/E ratio of 46.43. The analysis …

Smith & Nephew Expands Wound Care Portfolio in $22B Market

Smith & Nephew (SNN) is expanding its wound care portfolio and addressing the chronic wound management market, which is projected to grow to over $30 billion by 2030. The company recently launched two new innovations, ALLEVYN COMPLETE CARE Foam Dressing and RENASYS EDGE Negative …

Nephros Inc (NEPH) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Nephros Inc (NEPH), detailing its current price momentum score, identified support and resistance levels, and a summary of technical indicators and moving averages. According to the analysis, the stock is currently trading between $3.66 (resistance) and $3.01 …

Smith & Nephew PLC (SNN) Valuation: PE, PB & Fair Value Analysis

This article provides a valuation analysis of Smith & Nephew PLC (SNN), highlighting its current valuation score and P/E ratio. The company's valuation score is 5.83, ranking it 190 out of 199 in the Healthcare Equipment & Supplies industry. While the P/E ratio is …

Are Smith & Nephew (LSE:SN) And Convatec (LSE:CTEC) Defining The UK Healthcare Stocks Story?

Smith+Nephew’s TESSA™ Spatial Surgery System granted De Novo classification by the FDA sparking a generational leap in Sports Medicine for personalized planning and procedural innovation

Smith+Nephew has received De Novo classification from the FDA for its TESSA Spatial Surgery System, marking a significant advancement in Sports Medicine. The system utilizes AI, augmented reality, and advanced imaging for personalized planning and real-time navigation during arthroscopic procedures, initially focusing on femoral …

Smith+Nephew's AI system overlays a 3D bone model in ACL surgery

Smith+Nephew has received FDA De Novo classification for its TESSA Spatial Surgery System, marking a new category for intra-articular orthopedic stereotaxic navigation instruments. The TESSA system uses AI and cloud-based deep learning algorithms to create patient-specific 3D anatomical models from pre-operative scans, which are …